Visual Patterns

• • Code-like visual structure was reportedly observable but lacked sufficient clarity for transcription.
• • Wall-breathing effects were reported, consistent with altered visual processing under the substance condition.
• • Colored smoke-like visual phenomena occurred during nystagmus; the report does not establish whether these were directly related to the laser projection or were independent visual effects.
• • The apparent lack of focus may reflect reduced perceptual resolution, fluctuating accommodation, eye movements, or altered attention rather than absence of structured visual content.

Behavioral Patterns

• • The participant observed the projected pattern but did not attempt detailed transcription because of poor visual clarity.
• • The experiment appears exploratory and single-subject, with qualitative ratings rather than standardized behavioral or perceptual performance measures.
• • The participant judged MDA to be unsuitable for COR documentation despite reporting that code-like patterns could be seen.

Technical Patterns

• • A 650 nm red laser with reported power of 1 mW and a 5 m projection distance was used with a diffraction grating.
• • A 488 nm laser was also used, but its power, projection distance, and experimental role were not documented, limiting wavelength-based comparison.
• • The use of a diffraction grating provides a repeatable optical stimulus in principle, but grating specifications, projection surface, beam geometry, ambient illumination, and camera documentation were not reported.
• • The experiment used multiple laser wavelengths, creating a potential confound because differences in visibility could arise from wavelength, beam power, diffraction efficiency, or retinal sensitivity rather than from the psychoactive condition.

Scientific Significance

This observation adds a low-intensity, single-subject data point to the broader question of whether COR-like experiences can occur across different psychoactive compounds. The report suggests that MDA may permit perception of code-like structure while producing insufficient clarity for reliable observation or transcription. However, the findings do not establish that MDA caused the reported code, that the code was objectively present, or that MDA is less effective than other compounds, because there was no baseline condition, blinded comparison, dose-ranging design, or standardized outcome measure. The reported visual effects may also reflect general psychedelic alteration, nystagmus, optical artifacts, or interactions among these factors.

Methodological Notes

Strengths include documentation of dose, approximate psychedelic intensity, laser wavelength, laser power, projection distance, and use of a diffraction grating. Major limitations are the single-participant design, absence of a sober or placebo control, lack of repeated trials, incomplete specifications for the 488 nm laser, and reliance on retrospective qualitative description. Code visibility and clarity were not operationalized, and no independent observer, image-based record, transcription accuracy score, eye-tracking, or accommodation assessment was used. The 200 mg oral dose is pharmacologically consequential and carries potential acute risks; future work should use appropriate medical and ethical oversight, exclude unsafe self-experimentation, and document adverse effects and physiological variables. The apparent inconsistency between the stated use of two lasers and the listed technical parameters should be resolved.

Recommendations

Future experiments should pre-register operational definitions for code onset, clarity, persistence, complexity, and transcription accuracy; use repeated within-subject sessions with sober/placebo and comparator conditions; and separate wavelength effects by testing one laser at a time with matched optical parameters. Record laser power, beam diameter, diffraction-grating specifications, projection surface, distance, ambient light, exposure duration, and viewing geometry. Standardized photographs or video, independent blinded raters, structured participant reports, and objective visual-performance tasks would improve reliability. Eye movements, nystagmus, accommodation, sleep, prior drug exposure, and baseline visual phenomena should be recorded as potential confounders. A dose-ranging design should not be pursued through unsupervised use; any pharmacological comparison should occur only under approved safety and ethics procedures.